Eco R1 Capital, LLC Crispr Therapeutics Ag Transaction History

Eco R1 Capital, LLC

$2.31 Billion
Q3 2024

A detailed history of Eco R1 Capital, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Eco R1 Capital, LLC holds 1,389,276 shares of CRSP stock, worth $56.6 Million. This represents 2.83% of its overall portfolio holdings.

Number of Shares

1,389,276

Previous 1,389,276 -0.0%

Holding current value

$56.6 Million

Previous $75 Million 13.0%

% of portfolio

2.83%

Previous 2.65%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$60.67 - $89.12 $84.3 Million - $124 Million	1,389,276 New	1,389,276 $94.7 Million
Q1 2022 May 16, 2022	SELL	$53.19 - $79.24 $57.3 Million - $85.4 Million	-1,077,483 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $75.5 Million - $120 Million	1,077,483 New	1,077,483 $81.7 Million
Q2 2020 Aug 14, 2020	SELL	$38.5 - $76.05 $1.17 Million - $2.32 Million	-30,510 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $1.03 Million - $1.91 Million	30,510 New	30,510 $1.29 Million
Q3 2019 Nov 14, 2019	SELL	$40.99 - $52.56 $66 Million - $84.6 Million	-1,610,250 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$35.45 - $48.2 $9.5 Million - $12.9 Million	-268,027 Reduced 14.27%	1,610,250 $75.8 Million
Q1 2019 May 15, 2019	BUY	$28.02 - $40.87 $46.8 Million - $68.2 Million	1,669,427 Added 799.34%	1,878,277 $67.1 Million
Q4 2018 Feb 14, 2019	SELL	$22.73 - $42.34 $6.62 Million - $12.3 Million	-291,150 Reduced 58.23%	208,850 $5.97 Million
Q3 2018 Nov 14, 2018	BUY	$44.35 - $65.71 $22.2 Million - $32.9 Million	500,000 New	500,000 $22.2 Million

Others Institutions Holding CRSP

# of Institutions

490

Shares Held

58M

Call Options Held

1.1M

Put Options Held

1.9M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.18B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eco R1 Capital, LLC with notifications on news.

Account

Eco R1 Capital, LLC Crispr Therapeutics Ag Transaction History